Anhui Fengyuan Pharmaceutical operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Anhui Fengyuan Pharmaceutical with three other
companies in this sector in China:
SSY Group Ltd
sales of 2.66 billion Chinese Renmimbi [US$392.81 million]
of which 96%
was Intravenous Infusion Solution and Others),
Hunan Jingfeng Pharmaceutical Co Ltd
(2.58 billion Chinese Renmimbi [US$381.81 million]
of which 97%
was Medicine Manufacturing), and
Guizhou Bailing Group Pharmaceutical Company Limited
(2.59 billion Chinese Renmimbi [US$383.02 million]
of which 91%
During the year ended December of 2017, sales at
Anhui Fengyuan Pharmaceutical were 2.58 billion Chinese Renmimbi (US$380.99 million).
increase of 26.8%
versus 2016, when the company's sales were 2.03 billion Chinese Renmimbi.
Sales of Other Operations saw an increase
that was more than double the company's growth rate: sales were up
83.4% in 2017, from
36.72 million Chinese Renmimbi to 67.35 million Chinese Renmimbi.
Anhui Fengyuan Pharmaceutical also saw significant increases in sales in
Medicine Manufacturing (up 41.1% to 1.01 billion Chinese Renmimbi)